<DOC>
	<DOCNO>NCT01226563</DOCNO>
	<brief_summary>The primary objective evaluate safety effectiveness IK-5001 device prevention ventricular remodel congestive heart failure administer subject successful percutaneous coronary intervention stent placement ST segment elevation MI ( STEMI ) .</brief_summary>
	<brief_title>IK-5001 Prevention Remodeling Ventricle Congestive Heart Failure After Acute Myocardial Infarction</brief_title>
	<detailed_description>Heart failure significant problem , carry substantial mortality . According study , leave ventricular ( LV ) remodel contributes independently heart failure progression . Prevention reversal LV remodeling correlate decreased risk death heart failure event . IK-5001 implantable device use subject recent myocardial infarction ( MI ) . The IK-5001 device show directly halt remodel process occur follow acute MI . IK-5001 replaces damage extracellular matrix ( ECM ) degrade infarction , support damage myocardial tissue , prevent local dyskinesis , decrease wall stress . Because minimal interaction myocardium , mechanism action , lack specific pharmacologic activity elimination behavior , IK-5001 medical device concurrence Global Harmonization Task Force 's harmonized definition medical device .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Alginic acid</mesh_term>
	<criteria>Inclusion criterion : Subjects must meet follow inclusion criterion participate trial : 1 . The subject ≥ 18 year age . 2 . The subject give informed consent . 3 . The subject experience large STEMI define follow criterion : Peak cardiac enzyme value within 48 hour symptom onset follow : Creatine kinase MB fraction ( CKMB ) &gt; 30 x upper limit normal OR Troponin I &gt; 200 x upper limit normal OR Troponin T &gt; 60 x upper limit normal AND least 1 follow 3 criterion : Delayed presentation PCI &gt; 6 hour onset symptom Significant new Q wave ≥ 2 anterior lead anterior ST segment elevation least 3 mm persistent 24 hour PCI New onset CHF ( Killip class 34 ) cardiogenic shock persistent 24 hour PCI AND least 1 follow 2 criterion : MI ≥ 20 % Single Photon Emission Computed Tomography scan ( SPECT ) cardiac Magnetic Resonance Imaging ( MRI ) defect appropriate distribution Ejection fraction ≤ 35 % wall motion abnormality appropriate distribution baseline image assessment 4 . The subject successful PCI stent within 48 hour symptom onset , residual stenosis le 20 % infarct relate artery great equal thrombolysis myocardial infarction ( TIMI ) 2 flow . Subjects undergo rescue PCI thrombolysis delay presentation ongoing ischemia may enrol . 5 . For Germany : Patients determine Killip class 4 time device deployment eligible randomization . 6 . For Germany : If SPECT use determination MI size order meet inclusion criterion , SPECT must previously perform part standard clinical care . SPECT perform solely qualify patient study Germany . Exclusion criterion : Subjects exclude participate trial ANY follow exclusion criterion meet : 1 . Any subject cardiogenic shock require mechanical ventilation mechanical support time deployment . Subject must mechanical support prior deployment . 2 . Need urgent coronary artery bypass graft ( CABG ) 3 . Clinically significant valvular heart disease plan surgical correction transcatheter aortic valve implantation ( TAVI ) 4 . Uncontrolled ventricular arrhythmia 5 . Renal insufficiency calculate creatinine clearance le 30 mL/ minute . See Appendix A determining estimate creatinine clearance . 6 . Clinically significant hepatic insufficiency 7 . Inadequate imaging window ( define inability visualize endocardial border least 16 17 segment apical four chamber apical two chamber view without foreshorten ) arrhythmia would preclude adequate 3D image transthoracic echocardiography local baseline echo assessment 8 . Nonambulatory prior index MI 9 . The subject participate another trial investigational agent within 30 day prior randomization . 10 . Subject receive resorbable stent part PCI . 11 . The subject pregnant breastfeeding . Women childbearing potential negative urine pregnancy test prior randomization . 12 . Any concurrent condition , opinion investigator , would prevent completion clinical trial , include inability comply follow requirement . 13 . For Germany : In investigator 's opinion , patient expect survive ≥12 month . 14 . For Germany : 24 hour prior device deployment , patient serum calcium level great upper limit normal determine local laboratory .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>STEMI</keyword>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Left Ventricular Remodeling</keyword>
	<keyword>Devices , Medical</keyword>
</DOC>